British Cardiovascular Intervention Society. BCIS audit returns. Adult interventional procedures. Jan 2013 to Dec 2013 [online; accessed 24 August 2015]

British Heart Foundation. Heart statistics [online; accessed 07 July 2015]

Dave RM. Improving outcome of STEMI PCI: Preliminary results of Crystal AMI trial. Presentation at LUMEN conference, 26–28 February 2009, Miami Beach, USA [online; accessed 07 July 2015]

Elgendy IY, Huo T, Bhatt DL et al. (2015) Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials. Circulation: Cardiovascular Interventions 8: e002258

Gatto L, Imola F, Romagnoli E et al. (2014a) Residual intrastent thrombus after primary angioplasty is associated with MACE at follow up. Insight from the COCTAIL II Study. Poster presented at Transcatheter Cardiovascular Therapeutics 2014 meeting, 13–17 September 2014, Washington DC, USA. Journal of the American College of Cardiology 1: B40–B41

Gatto LE, Romagnoli E, Imola F et al. (2014b) Residual intrastent thrombus after primary angioplasty identifies patients with worsened microcirculatory indexes. Insights from the Coctail II. Poster presented at the National Congress of the Italian Society of Invasive Cardiology, 14–17 October 2014, Genoa, Italy. Giornale Italiano di Cardiologia 15: e45

Gibson C, Maehara A, Lansky J et al. (2011) Rationale and design of the INFUSE-AMI study: A 2×2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 161: 478–86.e7

Hamza M, Galal A, Suweilam S et al. (2014) Local intracoronary eptifibatide versus mechanical aspiration in patients with acute ST-elevation myocardial infarction. International Journal of Vascular Medicine 2014: 294065

Medicines and Healthcare products Regulatory Agency. Consent decree for medical devices supplied by Atrium Medical (Maquet) [online; accessed 09 July 2015]

Prati F, Capodanno D, Pawlowski T et al. (2010) Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. Journal of the American College of Cardiology: Cardiovascular Interventions 3: 928–34

Prati F, Di Giorgio A, Manzoli A. (2011) Focus on the Coctail study. Interventional Cardiology 3: 275–81

Prati F, Di Vito L, Ramazzotti V et al. (2013) Randomised trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study. Journal of Cardiovascular Medicine 14: 364–71

Stone G, Maehara A, Witzenbichler B et al. (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. Journal of the American Medical Association 307:1817–26

Stone G, Witzenbichler J, Godlewski J et al. (2013) Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction one-year results from the INFUSE-AMI trial. Circulation: Cardiovascular Interventions 6: 527–34

Svilaas T, Vlaar P, van der Horst I et al. (2008) Thrombus aspiration during primary percutaneous coronary intervention. New England Journal of Medicine 358:557–67

Thiele H, Schindler K, Friedenberger J et al. (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 118: 49–57

Tomey MI, Mehran R, Brener SJ et al. (2015) Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). American Heart Journal 169: 86–93

Waksman R, Pakala R (2009) Drug-eluting balloon. The comeback kid? Circulation: Cardiovascular Interventions 2: 352–8

Zhao X‑Q, Theroux P, Snapinn SM et al. (1999) Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 100: 1609–15